Serum tartrate-resistant acid phosphatase 5b as a marker of bone metastases in prostate cancer
J Bone Miner Res 18 (Suppl. 1), Abstract SA094
Alatalo SL1, Ala-Houhala M2, Korpela J2, Halleen JM1, Väänänen HK1, Koskinen A3, Helenius H3, Salminen E2
1Department of Oncology, University Hospital
2Institute of Biomedicine, Department of Anatomy
3Biostatistics, University of Turku, Finland
Introduction
Prostate cancer (PC) is the most common cancer and the second common cause of cancer related death among Finnish men (www.cancer.fi). Bone metastases (BM) occur in approximately 90% of patients with advanced PC1 and these can cause skeletal events and suffering to the patients, significant resource requirements and costs to the care providers. Therefore it is important to seek novel methods and assays for prediction of severity of metastatic changes in bone metabolism.
Tartrate-resistant acid phosphatase 5b (TRACP 5b) is secreted by osteoclasts during bone resorption. It has been demonstrated that serum TRACP 5b is a specific and sensitive marker of bone resorption. It is elevated in conditions with increased bone resorption such as osteoporosis and metastatic breast cancer, and decreased during antiresorptive treatment.
Aim of the study
The purpose of this cross-sectional study was to evaluate the potential value of serum TRACP 5b as a marker of bone metastases in prostate cancer. Serum TRACP 5b was compared with the known prostate cancer marker prostate specific antigen (PSA) and with the bone formation marker total alkaline phosphatase (ALP).